4D Molecular Therapeutics FDMT Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's other income (expense)?
- 4D Molecular Therapeutics (FDMT) reported other income (expense) of $4.86M in Q1 2026.
- How has 4D Molecular Therapeutics's other income (expense) changed year-over-year?
- 4D Molecular Therapeutics's other income (expense) decreased by 14.0% year-over-year, from $5.65M to $4.86M.
- What is the long-term trend for 4D Molecular Therapeutics's other income (expense)?
- Over 3 years (2022 to 2025), 4D Molecular Therapeutics's other income (expense) has grown at a 97.1% compound annual growth rate (CAGR), from $2.54M to $19.44M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.